Inhibitor Therapeutics Inc (QB) (INTI)

$INTI: Now at $0.09.....................

Would love to see an updated Investor Deck on this one..............

https://d1io3yog0oux5.cloudfront.net/_c69f5b1521d8be345040abd6d8242b6a/inhibitortx/db/2271/21556/pdf/%2803+12+24%29+INTI+-+Corporate+Deck.pdf

Its been a while since they last put something out.


GO $INTI

It is interesting

NEWS today. Sitting on $9m in cash. Check out the CEO - founder of Laser Vision,

Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
A critical milestone completed on the mission path of commercializing Itraconazole in numerous oncology indications.

TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the "License") with Johns Hopkins University (JHU) for their U.S Patent 8,980,930 (Canada Patent 2,572,223) "New Angiogenesis Inhibitors". Angiogenesis Inhibitors, as described by the National Cancer Institute, are unique cancer fighting agents as they block the growth of blood vessels that support tumor growth rather than blocking the growth of the tumor cells themselves. Inventors affiliated with JHU developed this patent, listing Itraconazole as an Active Pharmaceutical Ingredient (API) that has anti-angiogenic properties.

The License notes field of use is for use in Prostate Cancer, Basal Cell Carcinoma including Basal Cell Carcinoma Nevus Syndrome (an orphan oncology disease), and Lung Cancer, all of which emphasize a significant unmet need. Inhibitor believes the License is a mutually beneficial agreement, yielding a modest annual royalty rate with milestone payments typical to such a license.

Within the literature Head et al1 explains the long-term recognition that angiogenesis is a requirement for tumor growth and metastasis and that growing tumors can promote angiogenesis by secreting proangiogenic factors such as VEGF, basic FGF, EGF and others. These proangiogenic factors stimulate the proliferation, migration, and differentiation of the endothelial cells that make up the inner layer of all blood vessels, causing them to form new vessels that grow towards the source of these factors, this process termed "tumor angiogenesis". It is identified that the major target of itraconazole in endothelial cells is VDAC1. VDAC1 knockdown profoundly inhibits mTOR activity and cell proliferation in HUVEC revealing a previously unknown connection. Inhibition of VDAC1 by itraconazole leads to an increase in cellular AMP:ATP ratio and activation of the AMP-activated protein kinase (AMPK), an upstream regulator of mTOR. VDAC1-knockout cells are resistant to AMPK activation and mTOR inhibition by itraconazole, demonstrating that VDAC1 is the mediator of this activity. In their testing it was found that by using a phenotypical approach starting with the effect of itraconazole the G1-S cell cycle transition of the endothelial cells, itraconazole specifically inhibited the mTOR signaling pathway by downregulating the kinase activity of mTORC1.

Chow Et Al2 completed a study utilizing RNA sequencing to decipher the biological pathway propelling BCC growth. From the assay results, it was observed that BCCs exhibited a considerable amplification in the expression of the mTOR pathway. This pathway plays an essential role in regulating angiogenesis, the growth of new blood vessels from pre-existing ones. Thus, this indicates that it is the heightened activity of the mTOR pathway, and the consequent enhancement of angiogenesis, that stimulates the growth.

Data from Inhibitor's completed Phase 2b SCORING Trial complements the literature with reference to the Lesion Response of the study which shows that across the 477 target lesions the investigators reported reductions of any size from baseline for 399 (83.65%) lesions, 64 (13.42%) had no change and 14 increased in size. A pre-determined reduction of 30% or greater was seen in 275 of the 477 (57.7%) target lesions, including 130 lesions which resolved completely (27.3%). A total of 13 new 'surgically eligible' lesions across 8 of the 38 patients developed over the duration of the study.

For more information about Inhibitor and our mission please visit us on our website (www.inhibitortx.com) and for any further or specific queries you may have please visit our contact us page, submit your details/query, and a representative will be happy to get in touch.

$INTI: Haven't forgotten about that 400k bidder......


They get here early so that they can capitalize on whats coming down the
pipe.


We're due for some monster news with Big time Bidders like that.



Took some more today.......... deploying yesterdays $PMCB profits


Won't take much at all to get to $1 and beyond


Only 26k shares to go

GO $INTI

$INTI: Mayne Pharma positive results with Tolsura


Page #14 of Investor Deck


http://www.maynepharma.com/media/2478/mayne-pharma-2021-half-year-investor-presentation.pdf



GO $INTI

$INTI: Suba-Itraconazole with Mayne Pharma happening.




https://inhibitortx.com/technology/suba-itraconazole/


https://www.contagionlive.com/view/fda-approves-subaitraconazole-for-treatment-of-systemic-fungal-infections


In Phase 2 testing conducted by INHIBITOR, SUBA-Itraconazole demonstrated BCC target tumor inhibition without causing the classical Hedgehog (Hh) pathway adverse events in patients with BCCNS, leading to the promise of improved tolerability and the potential to maximize efficacy enabled by continuous Hedgehog pathway inhibition to manage this genetic condition. INHIBITOR’s majority shareholder and licensing partner, Mayne Pharma, assumed further development for this indication and is currently planning the launch of global testing of SUBA-Itraconazole for treatment of BCC lesions in patients with BCCNS in 2021.









GO $INTI

$INTI: Hellllloooooooooo market bidders

We remember that huge 400k bid on Friday.


She's ready to rip to nicely over $1



Another $TZPC in the making :)


Now only $0.25



GO $INTI

$INTI: MONSTERRRRRRRRRRRRRRR BIDDDDDDDDDDDDERRRRRRRRRRR



Now you know we gonna go ballistic....... just like that.


NOTHING in the way to over $1 !!!!!!!





GO $INTI

$INTI : Only 10k to get over $1


Only 130k loaded today. Now $0.32


Wake up market participants :)



GO $INTI

Garbage!

This security continues to be crap! Its probably going. No volume! Poor stewardship of investors and investment.

#shell?
#deceive
#ripoff

This is another dog! Is there any logical reason to remain in this security? Come on. Throw us something!

I was trying to dump 5K shares and couldn’t do it. Unbelievable...

Real seller on this piece of crap today.

I sold my shares in front of him @ .051. Who knows the next day this thing will trade more than 1000 shares, not liquid at all

Not sure what’s going on with company, but again, this like several other securities should be doing better. I guess its the corona-factor holding it back.

Keeping the faith!

Trading 0.07

Let’s go! Get something going!

Nice bid today, someone wants in. 100k bid at .07

Anyone hearing anything? It’s awfully quite with no news! What’s going on INTI?

These companies that don’t keep their shareholders updated on activities hurt their brand, pps, and shareholder confidence. I don’t get it!

Little volume today

Highest close in two weeks. Volume still low. (on this board too)

I agree with you that the low float and no dilution are very appealing.

Few people got tired of waiting and have sold into the bid it seems. Might be a while before this moves again

$INTI: I know.... the rationale is strong


Just the recognition wanes.
Feels like a TSLA stock.
Gets no love....... but when it rolls it will.


Usually when it lingers here is when you have those Unexpected pops.

Like that NCRA call you made once.


Remember how it lingered for ever.

That was epic........ one of the best CALLS I've ever witnessed.


I'll never forget it !


GO $INTI

Forgot about this one. maybe can bounce

with the low float,no dilution(rare),insane potential drives insane runs

looks great chart wise,rarely do any look good on all chart times(INTI does),min,daily,weekly,up to 3 to 5 years,INTI is just starting a 2 year+ breakout on macd ,last time was a nice long run
I am in and holding fast,it is accumulating big,so someone knows something and is loading,also board of directors agreed to take a cut in pay until june 30th,who does that,not scammers!!!,they know big things are coming!!!!

Volume = gone on this puppy. Guess it's one of those that trades by appointment

inhibitors ability to fight infection of virus ??

daily,50day chart,steady uptrend,accumulation,could explode any time

study updates,(enroll complete,ect)will drive pps sky high

$INTI: Solid Bio here... FDA tailwinds


And Mayne Pharma backing.


What more could you ask for.


TUTE investing will buy this up on this value.


I'm buying as well.


GO $INTI

the next up-tick from here,puts INTI up 86%,wont take much to rally

Could we get a chart going here please.
I have great software on my devices but some Ihubbers don't and
rely on the simplicity of it on just about every ticker.
Just saying. $INTI.

wont take much for huge run up,few shares are avaliable

#6 on breakout board,ppl are watching for rally

long chart,higher lows,still looks great,watch for rally up

Picked up 5K. Coming into this one slowly. Looks like they have it together, but we'll see.

$LBRMF will have its day.


This story here is different as well.



Gerald Group is market making for Labrador.


Mayne has Inhibitors backing.


You just have to look for what the stimulants are.


Can't get them right 100% of the time.

Ok. Believing. Labrador sucked my life force maybe rebound here Go $INTI.

$INTI: I know... it looks worse than it is


But I'm averaging down.

It won't take much effort to double from here either.

Very easy to do from $0.064.


So I know this should be over $0.50


A time comes when the value isn't this cheap anymore.


Saw the same thing Happen on $SAVA.... and then it popped hard.


Those that saw thru it..... profited.


ATB

I am one of your 700+ followers and you are very good at your pics this is going wrong direction for my liking but perhaps it will rebound Good luck everyone $INTI.

$INTI: Only 2k down to $0.06


HA............ thats NOTHING


Nice try






GO $INTI

$INTI: Mayne is gonna throw more money at $INTI


No negative impact to shareholder price.

They wanna make sure that as they go thru Phase 2 trials, they
have everything they need to achieve success.


After all... 9% royalties will help pay for their investment in the
not too distant future.

MAYNE investing in INTI is a big boost of confidence.


GO $INTI

Same, picked up a few

$INTI: Thank you.

Its not everyday you see ticker with FDA IND clearance laying in the
trenches here at $0.07


Gifts abound.



GO $INTI

More cheapies up for sale

$INTI: Thanks..... $SAVA was my big BIOrunner so far


Called that on the pullback to $1.50.... sold at $10.

Check the board.



$INTI is gonna be next.


No reason why $INTI can't easily get to $5/sh



These cheap valuations right now and no dilution, no offering and financing
from MAYNE.



Gotta Love it.



GO $INTI

Loved it.

$INTI: Why'd the FDA give $INTI IND-Clearance

I think the signs are on the table.


The sense of urgency couldn't be any greater right now.


Time to update the technology and treatment efficacy.... without Chemo.

Immunotherapy the only way to go.


$INTI in the thick of it... along with MAYNE Pharma


How you all like my $FORU call yesterday ?


$INTI is next :)



https://www.thestar.com/news/gta/2019/12/30/shortages-expected-as-mcmaster-becomes-the-worlds-only-supplier-of-medical-isotope-used-to-treat-prostate-cancer.html




GO $INTI

$INTI: No problems loading here


Maybe its just me........ downside sellers miniscule relatively speaking.


But if they sell more... I'll buy more


38k today






GO $INTI

Been trying to add all morning with no luck...ugh!